Hormone receptor-positive breast cancer accounts for most newly diagnosed mammary malignancies globally. For years, clinicians have relied on fulvestrant, a potent pure selective estrogen receptor degrader (SERD), to manage endocrine-resistant disease. However, low aqueous solubility requires clinicians to administer fulvestrant through bulky intramuscular depot injections. Consequently, patients experience procedural anxiety, local site discomfort, and potential nerve injury. To solve these clinical challenges, pharmaceutical scientists have engineered an advanced platform for transdermal fulvestrant delivery using high-permeation vesicles incorporated into a hydrogel matrix. This novel noninvasive strategy provides efficient localized treatment, reduces systemic adverse reactions, and improves patient adherence.

Overcoming the Limitations of Intramuscular SERD Therapy

Fulvestrant effectively downregulates estrogen receptors and arrests tumor proliferation without partial agonist activity. Nevertheless, its profound lipophilicity and poor oral bioavailability necessitate parenteral delivery. Currently, clinicians must inject 500 mg monthly through two distinct 5 mL deep gluteal intramuscular injections. Therefore, patients frequently report injection site soreness, induration, hematoma formation, and sciatica. Furthermore, intramuscular dosing poses significant bleeding risks in patients receiving concomitant anticoagulant therapy or those suffering from thrombocytopenia.

Moreover, frequent hospital appointments for parenteral administration increase economic and physical burdens on oncologic patients. In contrast, topical drug administration offers direct local therapeutic action while bypassing first-pass hepatic metabolism. Because breast neoplasms often reside near the cutaneous surface, localized transdermal delivery creates high regional drug concentrations right inside target mammary tissues. Unfortunately, the stratum corneum acts as a formidable biological barrier that resists the passive penetration of large, lipophilic molecules. Consequently, overcoming this rigid cellular barrier requires specialized lipid carriers tailored for deep cutaneous transport.

Optimizing Transdermal Fulvestrant Delivery With High-Permeation Vesicles

To overcome epidermal resistance, researchers formulated ultra-flexible high-permeation vesicles (HPVs). These nanocarriers combine soya phosphatidylcholine with a customized ternary mixture of chemical penetration enhancers. Specifically, the formulation team integrated sodium oleate (SO), diethylene glycol monoethyl ether (DEGEE), and propylene glycol (PG). Sodium oleate perturbs intercellular lipid bilayers, while DEGEE and PG fluidize the lipid matrix and alter drug thermodynamic activity within the skin.

Furthermore, investigators utilized a D-optimal mixture design to refine vesicle dimensions, polydispersity index (PDI), and entrapment efficiency. The optimal carrier composition contained 80% phospholipid and 20% permeation enhancer blend in a 6:1.5:2.5 ratio of SO, DEGEE, and PG. As a result, the optimized vesicles exhibited an average hydrodynamic diameter of 94.02 nm, a low PDI of 0.241, and a strongly negative zeta potential of -38.6 mV. Notably, the high practical drug loading reached 8.58%, whereas encapsulation efficiency exceeded 85.7%. Crucially, the vesicles displayed a deformability index of 1.62, which allows the nanocarriers to squeeze intact through narrow aqueous pores across the stratum corneum.

Formulation and Cutaneous Retention of the Carbopol Hydrogel

Following successful nanocarrier synthesis, investigators dispersed the optimized vesicles into a 1.5% w/v Carbopol 934P hydrogel (FLV/HPVs-gel). This polymer network creates a stable, bioadhesive topical matrix that prevents rapid runoff and extends contact time on the skin surface. For rigorous scientific benchmarking, the researchers compared this formulation against conventional free-drug gel (FLV-gel) and standard liposome-loaded gel (FLV/Lipo-gel) using equivalent drug concentrations.

Subsequently, in vitro permeation experiments revealed that the FLV/HPVs-gel system achieved nearly eight-fold higher drug permeation than plain FLV-gel. Additionally, the platform delivered approximately three-fold higher transdermal penetration than conventional liposomes. Confocal laser scanning microscopy verified that the ultra-flexible vesicles penetrated deep into the dermis rather than accumulating uselessly on superficial layers. Therefore, this platform establishes a robust intradermal reservoir that sustains continuous, controlled fulvestrant release into adjacent tissues over prolonged durations. Furthermore, the Carbopol hydrogel exhibited shear-thinning rheological behavior, which ensures smooth topical spreadability and optimal patient convenience.

Pharmacokinetics and In Vivo Antitumor Efficacy

Pharmacokinetic investigations in pre-clinical models confirmed substantial systemic absorption and sustained tissue exposure following topical administration of FLV/HPVs-gel. Specifically, the peak plasma concentration (Cmax) rose approximately 8.3-fold compared with plain FLV-gel and two-fold compared with standard liposomal gel. Similarly, total drug exposure across 168 hours (AUC0-168 h) increased roughly 8.1-fold and 2.6-fold over free-drug gel and liposomal controls, respectively. Remarkably, topical FLV/HPVs-gel produced plasma concentration-time curves that closely matched conventional intramuscular fulvestrant depots.

Subsequently, investigators tested therapeutic performance in female mice bearing aggressive 4T1 mammary tumors. Among all topical cohorts, FLV/HPVs-gel generated the most pronounced tumor-suppressive response. Histopathological analyses demonstrated intense tumor cell necrosis and marked apoptotic cell death within the tumor core. Furthermore, fluorescent biodistribution assays proved that the deformability of high-permeation vesicles facilitated extensive intratumoral accumulation. In contrast, conventional non-deformable liposomes remained largely trapped within superficial dermal layers. Thus, the flexible vesicle-in-gel platform successfully delivered cytotoxic payloads directly into localized cancerous tissue.

Biocompatibility and Translational Horizons for Clinical Oncology

Patient safety and local tissue tolerance represent crucial benchmarks for any novel transdermal therapy. Accordingly, the investigators conducted comprehensive dermatological and systemic safety evaluations following sustained topical application. Transepidermal water loss (TEWL) measurements showed no disruption of the physiological skin barrier. Furthermore, microscopic analysis of treated skin tissue revealed intact epidermal architecture without signs of erythema, edema, or inflammatory leukocyte infiltration.

Similarly, systemic toxicity assessments supported the biocompatibility of the nanogel. Serum liver transaminases, blood urea nitrogen, and serum creatinine levels remained completely within normal physiological limits. Histological examination of vital organs, including the heart, lungs, liver, spleen, and kidneys, revealed no evidence of pathological organ damage or drug-induced microvascular injury. Consequently, these encouraging preclinical outcomes establish high-permeation vesicle-in-gel formulations as a safe, highly tolerable alternative to conventional parenterals. In routine oncology practice, replacing painful intramuscular injections with a self-administered topical hydrogel could dramatically reduce clinical burdens, eliminate injection complications, and elevate the overall quality of life for breast cancer patients.

Frequently Asked Questions

Why is intramuscular fulvestrant administration problematic for breast cancer patients?

Clinicians currently administer fulvestrant via two painful 5 mL intramuscular injections every month. Because the drug formulation possesses high viscosity, each slow injection causes notable pain, tissue tension, and localized soreness. Furthermore, patients face procedural risks such as gluteal hematoma, abscess development, and accidental sciatic nerve damage. Intramuscular administration also creates safety concerns for patients receiving anticoagulant therapies or individuals presenting with severe thrombocytopenia.

How do high-permeation vesicles enhance skin permeation through the stratum corneum?

High-permeation vesicles incorporate a synergistic ternary enhancer mixture of sodium oleate, diethylene glycol monoethyl ether, and propylene glycol. Sodium oleate disrupts structured lipid bilayers within the stratum corneum, whereas the glycols increase lipid fluidity and membrane flexibility. Consequently, these ultra-deformable nanocarriers deform under osmotic gradients, squeezing through tiny intercellular pores without rupturing to deposit high drug concentrations deep within underlying dermal layers.

How does the therapeutic efficacy of FLV/HPVs-gel compare with conventional formulations?

In animal tumor models, FLV/HPVs-gel demonstrated superior tumor growth suppression compared with plain drug gels and standard liposome formulations. The flexible vesicle architecture achieved an eight-fold increase in drug permeation and significantly expanded systemic drug exposure. Furthermore, deep dermal distribution permitted substantial intratumoral accumulation, producing plasma concentration-time profiles comparable to intramuscular fulvestrant without provoking local skin irritation or systemic organ toxicity.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Akhtar J et al. Potentiated Skin Permeation and Antitumor Efficacy of Fulvestrant-Loaded High-Permeation Vesicles for Localized Breast Cancer Treatment. ACS Biomater Sci Eng. 2026 Oct 20. doi: 10.1021/acsbiomaterials.6c01112. PMID: 42900870.

Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005.

Alwan LA, Abd Alhammid SN. Applications of nanoparticles in the transdermal delivery of chemotherapy against breast cancer: a mini-review. Iraqi J Pharm Sci. 2025;37(2S):271-280.